PRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical Trial

About this update from Prf Technologies Ltd.

Milestone supports advancement of PRF’s drop-less ocular drug-delivery platform into next-stage U.S. clinical development for post-cataract pain and inflammation TEL AVIV, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”), a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, together with its majority-owned subsidiary LayerBio, Inc., today announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug (“IND”) application for OcuRing™-K, enabling the initiation of a Phase II clinical trial in patients undergoing cataract surgery. The IND clearance marks an important regulatory milestone for PRF and advances the Company’s strategy to develop OcuRing™-K as a drop-less, sustained-release therapy designed to address pain and inflammation following cataract surgery. OcuRing™-K is a patent-protected, bio-erodible intraocular ring designed to deliver ketorolac through a single intraoperative application. The platform is intended to provide sustained, localized drug release at the surgical site, potentially eliminating the need for complex post-surgical eye-drop regimens that can burden patients and contribute to inconsistent compliance. Ehud Geller, Executive Chairman of PRF Technologies, commented, “FDA clearance of the IND for OcuRing™-K is a meaningful milestone for PRF and an important step in advancing our ophthalmic drug-delivery strategy. We believe OcuRing™-K has the potential to address a clear unmet need in cataract surgery by offering a drop-less, inside-the-eye, sustained-release approach designed to improve treatment consistency and simplify post-operative care. This IND clearance reflects the progress of the program to date and allows us to move into Phase II clinical development in the United States.” Following IND clearance and completion of trial-startup activities, PRF plans to initiate a multi-center Phase II clinical trial in the United States, with patient enrollment expected to begin in the second half of 2026. The study is expected to evaluate endpoints related to pain reduction, inflammation control, and overall safety. Cataract surgery is one of the most commonly performed surgical procedures worldwide, yet post-operative recovery often still depends on weeks of ...

View stock analysis, news, and events for Prf Technologies Ltd.